Assessing the efficacy of FDG-PET(18F-fluorodeoxy glucose positron emission tomography) in the early detection of RCC (Renal cell carcinoma) in patients with ESRD(End stage renal disease)

Assessing the efficacy of FDG-PET(18F-fluorodeoxy glucose positron emission tomography) in the early detection of RCC (Renal cell carcinoma) in patients with ESRD(End stage renal disease) - FDG-PET in RCC related with ESRD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009336

Enrollment

150

Registered

2012-11-19

Start date

2012-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal cell carcinoma related with end stage renal disease

Interventions

one injection of 18F-fluorodeoxy glucose, 5MBq/Kg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: End stage renal disease patient under hemodialysis

Exclusion criteria

Exclusion criteria: patients with lactation,pregnancy and suspected pregnancy

Design outcomes

Primary

Measure	Time frame
The incidence of abnormal uptake of FDG in kidney which would suggest the presence of malignancy.	—

Countries

Japan

Contacts

Public ContactHiromi Hirasawa

Gunma University Hospital department of nuclear medecine

h.hirasawa@gunma-u.ac.jp027-220-8407

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026